Viking Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-4.7%projected annual EPS growth
Analyst Coverage
19analysts covering
FY EPS (est.)
-$4.61next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 28 Oct 2026 |
Monitoring Framework
Key Performance Indicators
VK2735 Subcutaneous Phase III Trial Enrollment (VANQUISH-1 & VANQUISH-2) Quarterly100.0Target: 100% Enrollment Completed
Cash, Cash Equivalents, and Short-Term Investments Quarterly603MTarget: Maintain sufficient runway for Phase III trials
Quarterly Net Loss Quarterly-158.3MTarget: Manage within projected clinical development budget
Watch Items
- VK2735 Phase I Maintenance Dosing Study DataTrigger: Data release expected in Q3 2026Action: Evaluate safety, tolerability, and weight maintenance efficacy across weekly, bi-weekly, and monthly dosing cohorts.
- Initiation of Phase III Oral VK2735 TrialTrigger: Expected trial start in Q4 2026Action: Monitor regulatory clearance, protocol finalization, and first patient dosing milestones.
- Amylin Agonist VK3019 Phase I TrialTrigger: Expected initiation in Q2 2026Action: Track first-in-human dosing and initial safety/tolerability readouts for the DACRA program.
Research as of 19 Jun 2026